Nuzenio

Tradingview Compass Therapeutics

Tradingview Compass Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 4 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Compass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside - TradingViewTradingView · Thu, 06 Aug 2026 23:20:13 GMTCompass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 12:11:09 GMTCMPX: Strong pipeline progress and solid cash position support continued clinical development - TradingViewTradingView · Thu, 06 Aug 2026 11:32:04 GMTCMPX Q2'26 Earnings: revenue estimate is (600.00K USD) - TradingViewTradingView · Wed, 29 Jul 2026 07:00:00 GMT

Timeline

Thu, 06 Aug 2026 23:20:13 GMTCompass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside - TradingView
Thu, 06 Aug 2026 12:11:09 GMTCompass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary - TradingView
Thu, 06 Aug 2026 11:32:04 GMTCMPX: Strong pipeline progress and solid cash position support continued clinical development - TradingView
Wed, 29 Jul 2026 07:00:00 GMTCMPX Q2'26 Earnings: revenue estimate is (600.00K USD) - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Compass Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.